Objective: To compare 5-year lesion recurrence rates in primary nodular basal cell carcinoma treated with topical methyl aminolevulinate photodynamic therapy (PDT) or simple excision surgery.
T
OPICAL PHOTODYNAMIC therapy (PDT) is an attractive modality for the treatment of basal cell carcinoma (BCC), based on its generally favorable efficacy and adverse effect profile and its excellent cosmetic outcome. Moreover, because PDT is a noninvasive procedure causing minimal damage to surrounding tissue, it offers advantages over excision surgery, particularly for the treatment of lesions in cosmetically sensitive areas, such as the face. [1] [2] [3] However, long-term follow-up data of controlled clinical trials of topical PDT vs excision surgery (regarded as the treatment of choice for nodular BCC) 4, 5 are lacking. We performed a prospective, randomized, multicenter study of simple excision surgery vs topical PDT, using methyl aminolevulinate, a drug showing highly selective uptake by malignant cells, 6 in the treatment of primary nodular BCC. Initial data covering a 2-year follow-up demonstrated that methyl aminolevulinate PDT was an effective treatment for nodular BCC. Clearance rates of 93% (vs 100% for excision surgery) were seen after 3 months and 85% (vs 98% for excision surgery) after 12 months, with no significant difference between treatment groups. Methyl aminolevulinate PDT also gave a significant superior cosmetic outcome compared with excision surgery at 3, 12, and 24 months. 7 At 24 months, 5 lesions that initially cleared with methyl aminolevulinate PDT had recurred, compared with 1 after surgery.
The potential for lesion recurrence following PDT is an issue of clinical concern, particularly in the treatment of deeper (nodular) BCC. Nearly two-thirds of all recurrent BCC lesions appear in the first 3 years after treatment, with 18% appearing between 5 and 10 years posttreatment. 8 We therefore performed a 5-year follow-up to examine the sustained complete lesion response and recurrence rate over time for methyl aminolevulinate PDT vs excision surgery in patients with nodular BCC.
METHODS
European university hospital dermatology departments participated in a prospective, randomized study of methyl aminolevulinate PDT vs simple excision surgery in patients with nodular BCC. The study design and procedures have been detailed in a prior report. 7 Patients aged at least 18 years with previously untreated primary nodular BCC, suitable for simple excision surgery, were enrolled from the clinics of participating centers. The diagnosis of nodular BCC was confirmed by histological examination. Patients with more than 10 eligible lesions; lesions in the midface region, orbital areas, and ears; lesions with a longest diameter of less than 6 mm or more than 15 mm (face or scalp), more than 20 mm (extremities or neck), or more than 30 mm (trunk); and pigmented or morpheaform BCCs were excluded. Patients were enrolled from October 26, 1999, to August 29, 2000, and were followed up until October 12, 2005. All patients gave written informed consent before enrollment. The study was performed in accordance with the Declaration of Helsinki, with ethical approval obtained from the local ethics committee of each of the participating centers.
Eligible patients were randomized to treatment with PDT using methyl aminolevulinate cream, 160 mg/g (Metvix; PhotoCure ASA, Oslo, Norway, and Galderma, Sophia Antipolis, France), or excision surgery. 7 In the PDT group, lesion surface preparation was performed in a standardized manner between centers, before application of methyl aminolevulinate cream. Surface scale or crust was gently removed with a curette or scalpel blade, without anesthesia, insufficient to cause pain or bleeding. An occlusive and light-shielding dressing was applied, and after 3 hours, the area was illuminated with noncoherent red light (wavelength, 570-670 nm; total fluence, 75 J/cm Patients with a complete response at 3 months after the last treatment (ie, complete disappearance of the lesion as evaluated on clinical inspection by the same investigator [M.A.R., V.G., G.A.E.W., or P.W.]) were followed up at yearly intervals for 5 years after the last treatment. Any clinically suspected recurrence was confirmed by histological examination. Investigatorassessed cosmetic outcome was judged yearly for up to 5 years in all patients with a complete response in all lesions, using a 4-point scale 7 as follows: (1) excellent: no scarring, atrophy, or induration and slight or no redness or change in pigmentation compared with adjacent skin; (2) good: no scarring, atrophy, or induration and moderate redness or increase in pigmentation compared with adjacent skin; (3) fair: slight to moderate occurrence of scarring, atrophy, or induration; and (4) poor: extensive occurrence of scarring, atrophy, or induration.
Details of adverse events, including local phototoxicity reactions reported up to 3 months after last treatment, have been provided. 7 During the 5-year follow-up, any adverse events that led to discontinuation were documented.
The primary statistical analysis was based on the per protocol (PP) population, including all eligible patients who completed surgery or the first PDT treatment cycle and had a response assessment at 3 months or who completed the second PDT treatment cycle and received treatment in accordance with the study procedures. In addition, an intention-to-treat analysis was performed. The analysis populations (intention-totreat and PP groups) were almost identical and gave similar results in all aspects. Two patients in each treatment group (4 of 101) were excluded from the PP population. The present study therefore focuses on the population of primary interest (ie, the PP population). Analyses were performed independently (PAREXEL International GmbH, Berlin, Germany) using SAS statistical software (SAS Institute Inc, Cary, North Carolina).
Of primary interest during long-term follow-up was the histologically confirmed lesion recurrence rate. Lesion recurrence rates were the proportion of recurrent lesions, of all lesions that had a clinical complete response 3 months after treatment. They were presented with 95% confidence intervals (CIs), and the treatment difference was tested with the Fisher exact test.
A time-to-event approach was used to estimate lesion complete response rates over time, using all available information and keeping the original sample size and randomization scheme. The event of interest was failure, defined as nonresponse at 3 months after the last treatment or recurrence at the follow-up intervals of 1, 2, 3, 4, or 5 years.
Censoring occurred when a patient with a lesion in complete response discontinued for reasons other than treatment failure. Discontinuations or recurrences were only recorded at the yearly follow-up. Thus, the exact time when the event occurred was unknown. Furthermore, some patients had more than 1 lesion. The lesions formed clusters within these patients and therefore could no longer be regarded as independent observations. The interval censoring and the lesion clusters made the data unsuitable for standard procedures, such as the Kaplan-Meier or the life-table approach. Instead, a complementary log-log model suggested by Guo and Lin 9 was used. In a first step, a logistic regression using the complementary log-log link function was run with standard software (PROC LOGISTIC; SAS Institute Inc). In a second step, the standard errors of the estimates were adjusted for the dependencies in the data caused by the lesion clusters, as described using computer software (IML; SAS Institute Inc).
Recurrence rates could not be derived from the time-toevent model because the failure rates were a combination of nonresponse rates at 3 months after the last treatment and recurrence rates during later follow-ups.
The proportions of patients categorized with excellent or good overall cosmetic outcome were summarized with 2-sided 95% CIs. The treatment difference was tested with the Fisher exact test using the categories of excellent or good vs fair or poor.
RESULTS
Of 103 randomized patients, 101 were treated in the study, 52 with methyl aminolevulinate PDT and 49 with surgery. The PP population comprised 97 patients, 50 with 53 lesions treated with methyl aminolevulinate PDT and 47 with 52 lesions treated with excision surgery (Figure 1) . Four patients were excluded from the PP population, 1 in the methyl aminolevulinate PDT group with a major protocol violation (received a light dose less than that stipulated) and 3 for whom response at 3 months could not be assessed (in the surgery group, 1 died and 1 withdrew consent; and in the methyl aminolevulinate PDT group, 1 discontinued the study prematurely because of treatment-related pain). Forty-nine lesions in 46 patients treated with methyl aminolevulinate PDT and 52 lesions in 47 patients treated with excision surgery showed complete lesion response at 3 months and were included in the long-term follow-up.
Sixty-six patients, 31 treated with methyl aminolevulinate PDT and 35 treated with surgery, completed the 5-year follow-up evaluation with at least 1 lesion in complete response. Twelve patients, 10 treated with methyl aminolevulinate PDT and 2 treated with surgery, discontinued the study before the 5-year follow-up evaluation, with treatment failure in all lesions (Figure 1 ). Only 4 patients (2 in each treatment group) were truly lost to follow-up during the 5-year period. Eight patients (4 in each group) died during the follow-up, and 2 discontinued because of intercurrent disease.
The baseline characteristics of the 2 groups were similar. 7 The mean (range) age was 69 (40-95) years in the methyl aminolevulinate PDT group and 67 (38-82) years in the surgery group; there were 32 men and 20 women in the methyl aminolevulinate PDT group and 29 men and 20 women in the surgery group. Most patients in each group had 1 lesion (94% [47 of 50 patients] in the methyl aminolevulinate PDT group and 89% [42 of 47 patients] in the surgery group). In each group, most lesions were less than 20 mm in diameter and were located on the face or scalp or trunk or neck (Table 1) . However, the distribution of these lesions differed between the 2 groups. In the surgery group, there were more lesions on the face or scalp than on the trunk or neck, whereas in the methyl aminolevulinate PDT group, the distribution of lesions to these areas was similar (Table 1) . Most lesions in the methyl aminolevulinate PDT group were treated with 1 PDT cycle (41 of 53 lesions [77%]).
LESION RESPONSE AND RECURRENCE
A time-to-event analysis of lesion response over time showed that excision surgery was more favorable than methyl aminolevulinate PDT (Figure 2) . At 5 years af- ter last treatment, the sustained lesion complete response rate, estimated by the complementary log-log model, was 76% (95% CI, 59%-87%) for methyl aminolevulinate PDT compared with 96% (95% CI, 84%-99%) for excision surgery in the PP population (P=.01). Lesion recurrence was documented in 14% of lesions with complete response after 3 months treated with methyl aminolevulinate PDT, compared with 4% of lesions treated with excision surgery (P =.09) ( Table 2 ). The methyl aminolevulinate PDT group recurrences included 5 of 40 lesions given 1 treatment cycle and 2 of 9 lesions given 2 treatment cycles. No recurrences in the methyl aminolevulinate PDT group were observed from 3 to 5 years, and only 1 lesion treated with excision surgery recurred within this period. In the methyl aminolevulinate PDT group, there was no evidence that lesion recurrence was higher in larger lesions because recurrence was documented in 5 lesions with a maximum diameter of up to 10 mm and in 2 lesions with a diameter between 11 and 20 mm (Table 2) . Recurrence rates at 5 years were identical in the intention-to-treat population.
COSMETIC OUTCOME
In the PP population, outcome at 3 months rated as excellent or good was found in 36 of 44 patients (82%) (95% CI, 67%-92%) in the methyl aminolevulinate PDT group vs 15 of 45 patients (33%) (95% CI, 20%-49%) in the surgery group (PϽ.001). The overall cosmetic outcome 5 years after last treatment was also superior with methyl aminolevulinate PDT compared with excision surgery. At final assessment, outcome as rated by the investigators [L.E.R., M.A.R., R.L., R.C.Y., I.B., V.G., M.-A.R., A.A., and P.W.]was good or excellent in 27 of 31 patients (87%) (95% CI, 70%-96%) treated with methyl aminolevulinate PDT compared with 19 of 35 patients (54%) (95% CI, 37%-71%) treated with excision surgery (P=.007) (Figure 3) .
COMMENT
Findings from this long-term follow-up study add to evidence supporting a role for methyl aminolevulinate PDT in the treatment of primary nodular BCC. The cumulative 5-year lesion recurrence rate with methyl aminolevulinate PDT was 14% compared with 4% for excision surgery, the latter being consistent with the published low rate for this modality. 8, 10, 11 We anticipate that we have captured all relevant events and that a longer than 5-year follow-up would be unlikely to yield further recurrences because only 2 recurrent lesions were observed in the methyl aminolevulinate PDT group and 1 in the surgical group between 2 and 3 years' follow-up. There were no recurrent lesions observed in the methyl aminolevulinate PDT group and only 1 in the surgical group from 3 to 5 years' follow-up.
While the sustained lesion complete response rate at 5 years was statistically superior with excision surgery compared with methyl aminolevulinate PDT (96% vs 76%; P=.01), lesions treated with methyl aminolevulinate PDT showed a substantially better cosmetic outcome at 5 years, as assessed by the investigator, than those treated with surgery (P = .007). Thus, the results of our study indicate that, whereas simple excision surgery will generally remain the treatment of choice for nodular BCC amenable to this intervention, methyl aminolevulinate PDT is also an effective treatment. There are a number of instances (eg, when there are multiple lesions; when there are lesions in sites such as the lower leg, where there is poor healing; and when there are patients undergoing anticoagulation) in which excision can be challenging. Moreover, methyl aminolevulinate PDT may be more suitable for the treatment of lesions in cosmetically sensitive areas, such as the face (involving approximately 50% of lesions in the present study), where optimal cosmetic outcome is an important clinical consideration. Systematic reviews 4, 5, 8, 11 of treatment modalities for BCC highlight the lack of published long-term follow-up data from controlled clinical trials and advocate evaluation of 5-year lesion recurrence rates as a primary outcome in clinical studies. The lack of long-term data from randomized PDT studies has been a particular concern among dermatologists. 12 To our knowledge, we present the first randomized study to report cumulative 5-year recurrence rates in nodular BCC comparing topical PDT with the standard treatment of excision surgery. We conclude that the moderately low 5-year lesion recurrence rate with methyl aminolevulinate PDT documented in this study, together with the favorable long-term cosmetic outcome, supports a clinical role for this modality in the treatment of nodular BCC, particularly when avoidance of scarring is a priority. 
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